Optimal Clinical Trials
Optimal Clinical Trials is a New Zealand-based late-phase (Phase 1b-4) clinical trial site executing vaccine, metabolic, and older-adult studies for global pharma sponsors and CROs, leveraging access to roughly 75% of New Zealand's primary care patient database.
- Company typePrivate
- Founded2013
- HeadquartersAuckland, New Zealand
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Optimal Clinical Trials does
Optimal Clinical Trials is a New Zealand-based late-phase clinical trial site that executes Phase 1b through Phase 4 studies, with particular depth in vaccines, metabolic disease, and trials involving older adult populations. Founded in 2013 and headquartered in Auckland, the company operates as part of the broader NZCR Group network under NZCR Group Holding Ltd., giving it access to over 450 clinical research professionals across New Zealand and integrated Phase 1 through Phase 4 capability. The site serves global pharmaceutical sponsors and Contract Research Organizations, with named relationships including Pfizer, AstraZeneca, Roche, Eli Lilly, Moderna, GSK, AbbVie, and Syneos Health, and has achieved multiple global top-recruitment rankings across therapeutic areas.
The company's core operational asset is its access to approximately 153,000 patient records representing roughly 75% of New Zealand's primary care database, which materially accelerates recruitment and underpins its top-recruitment performance. Quality systems are anchored by ISO 9001 certification and multiple successful FDA audits, and a 2024 Net Promoter Score of 97 indicates exceptional satisfaction among sponsors and participants. The site has expanded beyond Auckland with a Christchurch location, providing national coverage across New Zealand's two largest population centers.
Optimal Clinical Trials generates revenue through project-based clinical trial service delivery, charging sponsors and CROs per-patient and per-trial fees for protocol execution, recruitment, and site management. Additional revenue attractiveness is supported by New Zealand's government-approved R&D incentive framework, which provides 15-43% tax advantages to research sponsors conducting studies in the country. The company has been recognized on the Deloitte Fast 50 index for revenue growth, reflecting strong historical expansion. Its primary customer segment is large-cap global pharma and top-tier CROs, with no visible exposure to SMB or long-tail sponsors.
Optimal Clinical Trials firmographics
Firmographics- Name
- Optimal Clinical Trials
- Legal name
- Optimal Clinical Trials Limited
- Website
- https://optimalclinicaltrials.com
- Company type
- Private
- Founded year
- 2013
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Optimal Clinical Trials is a New Zealand-based late-phase (Phase 1b-4) clinical trial site executing vaccine, metabolic, and older-adult studies for global pharma sponsors and CROs, leveraging access to roughly 75% of New Zealand's primary care patient database.
- Ownership category
- akta.pro rank
Optimal Clinical Trials industry classification
Industry- Product category
- Clinical Research Services
- NAICS
- Research and Development in the Physical, Engineering, and Life Sciences (54171), Medical and Diagnostic Laboratories (6215)
- SIC
- Services-Commercial Physical & Biological Research (8731), Services-Offices & Clinics Of Doctors Of Medicine (8011)
- akta.pro primary industry
- Clinical Trial Site Operations & Study Coordination (HLAGACAE)
- akta.pro secondary industries
- Clinical CROs (Phase I–IV) (HLAGAAAA), Precision Clinical Trials Enablement (patient matching, site matching, adaptive trials) (HLAAANAI), Clinical Development (Phase I–III Trial Design & Execution) (HLAIALAE)
Keywords
Where Optimal Clinical Trials is headquartered
LocationHeadquarters
- HQ city
- Auckland
- HQ country
- New Zealand
- HQ region
- Oceania
Offices3 records
Markets served
Optimal Clinical Trials business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure, Supply Chain
Revenue model
- Clinical Trial Services for Sponsors and CROs: The company conducts Phase 1b-4 clinical trials on behalf of pharmaceutical sponsors, biotech companies, and CROs. Revenue is generated through contractual agreements for conducting clinical research studies, including participant recruitment, data collection, and regulatory compliance services.
- Government R&D Incentives: As a government-approved R&D incentives provider, the company can access R&D tax benefits, providing 15-43% Research & Development tax advantage for sponsors running trials in New Zealand
Go-to-market motion2 records
Distribution channels4 records
Marketing channels6 records
Optimal Clinical Trials product offering
Product offeringCore offering
Optimal Clinical Trials is a New Zealand-based late-phase clinical research organization that conducts Phase 1b-4 clinical trials on behalf of pharmaceutical sponsors, biotech companies, and contract research organizations (CROs). The company specializes in vaccine trials, metabolic studies (obesity, diabetes), older adult research, and dermatology studies, offering rapid startup (4-6 weeks), large-scale patient recruitment, retention management, and quality data delivery across research sites in Auckland and Christchurch.
Product overview
Optimal Clinical Trials operates as a late-phase clinical research organization offering a unified service portfolio centered on clinical trial execution. The core offering comprises Phase 1b-3 clinical trial services spanning vaccine trials, metabolic studies, and older adult research programs. Supporting capabilities include a large patient recruitment database with access to 75% of New Zealand's primary care database, rescue site services for underperforming studies, and specialized dermatology research. The company delivers integrated services including rapid startup, patient recruitment, retention optimization, and quality data collection through its network of research sites in Auckland and Christchurch.
Differentiator
Problem solved
Functional benefit
Products and services
- Late-Phase Clinical Trial Services Comprehensive Phase 1b-3 clinical trial execution services including study design feedback, patient recruitment, retention management, and data collection for pharmaceutical sponsors and CROs.
- Vaccine Trial Services Specialized vaccine clinical trial services including rapid start-up, high recruitment, and quality data delivery for influenza, COVID-19, RSV, and combination vaccine programs.
- Metabolic Trial Services Clinical trial services for metabolic conditions including obesity, diabetes, and weight management studies, leveraging access to relevant patient populations.
- Older Adult Clinical Trial Services Specialized clinical research services targeting older adult populations with focus on conditions prevalent in aging, including respiratory diseases and metabolic disorders.
- Rescue Site Services Clinical trial rescue services to help sponsors recover underperforming studies through rapid startup, high recruitment, and quality data delivery.
- Atopic Dermatitis Research Services Specialized dermatology clinical trial services including expertise in EASI, Hanifin and Rajka criteria, IGA assessments, and experience with biologics including dupilumab trials.
- Patient Recruitment Database Access Access to diverse patient pools including over 153,000 potential participants, 1,300 atopic dermatitis patients, and coverage of approximately 75% of New Zealand's primary care database.
Quantifiable outcome
- 95-100% participant retention rates across studies
- +5 more outcomes
Companies that use Optimal Clinical Trials
Customer profileNamed customers29 records
Segments6 records
Ideal customer profiles3 records
Optimal Clinical Trials technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Optimal Clinical Trials partnerships and signals
Strategic signalPartnerships
Ten partnerships are on record, tiered core, flagship and minor.
- NZCR Group (New Zealand Clinical Research)coreOptimal is part of NZCR Group - Australasia's largest clinical trials group offering complete Phase 1-4 capability. This partnership enables Optimal to offer end-to-end clinical trial services from early phase through late-phase studies.
- Syneos HealthflagshipOptimal was chosen as a Syneos Health Catalyst Site. This partnership expands Syneos Health's clinical trial capabilities in New Zealand, with collaboration focusing on CNS and Vaccines therapeutic areas.
- Greenlane Medical SpecialistscorePartnership with Greenlane Medical Specialists Group (GLMS), a specialist organization of over 25 medical consultants covering 17 therapeutic areas. GLMS provides specialist expertise for feasibility, patient identification and recruitment, and specialist input for study procedures.
- Equillium BiominorServed as rescue site for Equillium Bio's Alopecia Areata clinical study, delivering 200% of recruitment target with 100% retention rate.
- Cue HealthminorPartnered with Cue Health for COVID-19 and Flu Nasal Testing Device Clinical Study. Optimal achieved First Patient-In globally for this study.
- Dr Falk PharmaminorPartnership with Dr Falk Pharma International for a clinical study researching a potential new treatment for coeliac disease, testing effectiveness in reducing symptoms and healing intestinal lining.
- GSKcoreClinical research site for GSK's Arexvy (RSV vaccine), contributing to FDA approval - the world's first RSV vaccine for older adults. Worked with PPD as CRO partner on this pivotal study.
- Esperion TherapeuticscoreKey research site for CLEAR Outcomes trials studying Bempedoic acid for cardiovascular risk reduction. Results presented at ACC.23 and published in NEJM. Worked with IQVIA as CRO partner.
- NovavaxcorePartnered on multiple vaccine trials including Phase 2 COVID-Influenza Combination (CIC) vaccine study. Novavax announced positive results from the trial evaluating safety and immune responses.
- New Zealand Story GroupminorFeatured by New Zealand Story Group to share the company's story of contributing to life-changing medical discoveries since 2013.
Scale indicators11 records
Recent moves8 records
Expansion highlights4 records
Optimal Clinical Trials competitors and assessment
Company assessmentBroad incumbents
- Syneos Health: Global CRO that has designated Optimal as a Catalyst Site for CNS and Vaccines. Comparable as a broader incumbent offering site network services that partially overlap with Optimal's late-phase offerings, though at much larger global scale.
- Parexel: Global CRO named as a partner in Optimal's customer roster. Comparable broad incumbent with late-phase clinical trial services that overlap with Optimal's offerings.
- ICON plc: Global CRO listed as an Optimal partner. Comparable as a broad incumbent offering late-phase site management and full-service clinical research that competes for the same sponsor budgets.
- Fortrea: Global clinical research organization named as an Optimal partner. Comparable broad incumbent offering late-phase site services that overlap with Optimal's core business.
- PPD (Thermo Fisher): Global CRO that partnered with Optimal on GSK's Arexvy RSV vaccine program. Comparable broad incumbent in late-phase clinical research serving the same sponsor base.
- IQVIA: Global CRO that partners with Optimal as a research site. Comparable as a broad incumbent that both competes for and sources late-phase trial work from independent sites like Optimal.
- Medpace: Global mid-sized CRO listed as an Optimal partner. Comparable in late-phase trial execution with overlapping therapeutic-area expertise in metabolic, vaccines, and CNS.
Direct peers
- Novotech: Asia-Pacific-focused CRO that both partners with and competes against Optimal for sponsor trial allocation. Highly comparable in APAC late-phase site services and is named as a CRO partner in Optimal's customer roster.
- New Zealand Clinical Research (NZCR): Optimal's parent group affiliate operating early-phase (Phase 1) trials in Australasia. Direct peer given shared ownership, overlapping investigator network, and complementary Phase 1-4 coverage for the same sponsor base.
Regional players
- Linear Clinical Research: Australia-based early- and late-phase clinical trials site in Perth. Comparable regional player offering sponsor-facing late-phase trial services across Australasia, though operating from a different geography within the same broader market.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
Optimal Clinical Trials social profiles
Digital presenceOptimal Clinical Trials compliance and trust
Trust signalCompliance2 records
Optimal Clinical Trials financial estimates
Financial estimateRevenue estimate
Valuation estimate
Optimal Clinical Trials leadership team
Management profileNumber of profiles
Profiles11 records
Optimal Clinical Trials funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Optimal Clinical Trials M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Optimal Clinical Trials
What does Optimal Clinical Trials do?
Optimal Clinical Trials is a New Zealand-based late-phase clinical research organization that conducts Phase 1b-4 clinical trials on behalf of pharmaceutical sponsors, biotech companies, and contract research organizations (CROs). The company specializes in vaccine trials, metabolic studies (obesity, diabetes), older adult research, and dermatology studies, offering rapid startup (4-6 weeks), large-scale patient recruitment, retention management, and quality data delivery across research sites in Auckland and Christchurch.
Is Optimal Clinical Trials a public or private company?
Optimal Clinical Trials is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Optimal Clinical Trials founded?
Optimal Clinical Trials was founded in 2013. It employs 11 to 50 people.
Where is Optimal Clinical Trials based?
Optimal Clinical Trials is headquartered in Auckland, New Zealand, in the Oceania region.
How does Optimal Clinical Trials make money?
Two revenue lines are on record. Clinical Trial Services for Sponsors and CROs are the primary driver. The others are government R&D Incentives.
Who are Optimal Clinical Trials's main competitors?
Broad incumbents on record are Syneos Health, Parexel, ICON plc, Fortrea, PPD (Thermo Fisher), IQVIA and Medpace. Direct peers are Novotech and New Zealand Clinical Research (NZCR). Linear Clinical Research is listed as a regional player.
Does Optimal Clinical Trials have an API?
No public API is recorded for Optimal Clinical Trials.
What industry is Optimal Clinical Trials in?
Optimal Clinical Trials's product category is Clinical Research Services. Its primary akta.pro industry code is HLAGACAE, Clinical Trial Site Operations & Study Coordination, with a secondary code of HLAGAAAA, Clinical CROs (Phase I–IV). Its NAICS code is 54171 and its SIC code is 8731.